Medtronic PLC (MDT) is a leading medical devices business with stocks listed in the US. It opened the day at US$79.25 after a previous close of US$79.08. During the day the price has varied from a low of USD78.43 to a high of USD79.3. The latest price was USD79.19 (25 minute delay). Medtronic is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Best for beginner
Our top pick for
Dividend investing
Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
| Open | US$79.25 |
|---|---|
| High | US$79.3 |
| Low | US$78.43 |
| Close | US$79.19 |
| Previous close | US$79.08 |
| Change | US$0.11 |
| Change % | 0.1391% |
| Volume | 6,063,267 |
| 52-week range | US$67.7076 - US$89.0388 |
|---|---|
| 50-day moving average | US$84.8772 |
| 200-day moving average | US$81.933 |
| Target price | US$94.18 |
| PE ratio | 26.0857 |
| Dividend yield | US$2.75 (3.18%) |
| Earnings per share (TTM) | US$3.15 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $79.19
| 1 week (2024-04-12) | -1.17% |
|---|---|
| 1 month (2024-03-19) | -5.85% |
| 3 months (2024-01-19) | -8.44% |
| 6 months (2023-10-19) | 9.45% |
| 1 year (2023-04-19) | -6.69% |
|---|---|
| 2 years (2022-04-19) | -28.15% |
| 3 years (2021-04-19) | -37.22% |
| 5 years (2019-04-18) | -5.97% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Medtronic shares trade at around 26x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5565. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$8.7 billion (£7 billion).
The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, Medtronic's shares have ranged in value from as little as US$67.7076 up to US$89.0388. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.771. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
| Revenue TTM | US$32.3 billion |
|---|---|
| Operating margin TTM | 19.17% |
| Gross profit TTM | US$21.7 billion |
| Return on assets TTM | 4.23% |
| Return on equity TTM | 8.17% |
| Profit margin | 13% |
| Book value | 38.952 |
| Market capitalisation | US$109.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 51.88% of net profits
Recently Medtronic has paid out, on average, around 51.88% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.18% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.18% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.75 per share.
Medtronic's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Medtronic's most recent dividend payout was on 11 April 2024. The latest dividend was paid out to all shareholders who bought their shares by 20 March 2024 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 12/31/2018) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.07/100
Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.28/100
Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9/100
Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.
Medtronic PLC was last rated for ESG on: 2019-01-01.
| Total ESG score | 26.86 |
|---|---|
| Total ESG percentile | 40.62 |
| Environmental score | 4.07 |
| Environmental score percentile | 5 |
| Social score | 15.28 |
| Social score percentile | 5 |
| Governance score | 9 |
| Governance score percentile | 5 |
| Level of controversy | 3 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Blinklab shares.
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a flat $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?